BEAM

Beam Therapeutics Inc.

NasdaqHealthcareBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Insider activity for last month from Oct 16 to Nov 16.

How these metrics are calculated

Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.

Total buying$00 buys
Total selling$600k1 sale
Net open-market−$600kBuying minus selling
Active insiders1Distinct reporting owners

BEAM transaction history

Newest filings · 20 transactions per page

Latest insider transactions

Form 4 filings from last month.
Newest company filings
InsiderActivityDisclosed valueFiled (ET)
Evans John M.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
Evans John M.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Repeat seller
The same owner reported more than one sale within 30 days.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$600kView disclosure →
Evans John M.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
$25.8kView disclosure →

Insider activity report

Calendar-month buckets within the selected date range

Latest filing: Oct 16, 2026

Open-market transaction mix · 1 transactions in the selected period
0 buys0%·100%1 sells

Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.

View exact monthly counts and disclosed values
Monthly activity within the selected period; unknown values remain unknown.
MonthBuysSellsAwards (A)Buy valueSell valueNet P/S value
Oct 2026010$0$599,595−$599,595
Nov 2026000$0$0$0

Distinct insiders active

Reporting-owner CIKs by month · peak Oct 2026 (1)
Oct 2026: 1 insidersNov 2026: 0 insiders
Oct 2026Nov 2026
1distinct insiders in selected period
Largest insider activity
By absolute net disclosed value · current transaction page
1 insider
  • EM
    Evans John M.CEO · 0 buys · 1 sale · 0 awards (A)
    −$574klast Oct 16
Filing, role and holdings details

Filing-only signals

Deterministic matches in the selected period

Recent filing activity
Most recent 3 transactions on this page · color = transaction code

Filing detail checks

Secondary metrics for the selected period
Largest buy—
Largest sale$600k
10b5-1 detected3
Amended rows0

Transaction codes

By Form 4 transaction code in selected period
3transactionstxns
  • M · Option exercise · dominant2 · 67%
  • S · Open-market sells1 · 33%

Activity by reported role

A joint filing can contribute to multiple roles
Chief executive officer3

Reported Holdings After

Separated by insider, security, and ownership type

Evans John M.Common Stock · Direct
1.07M1.05MOct 16, 2026Oct 16, 2026
1,047,205Oct 16, 2026
Evans John M.Stock Option (Right to Buy) · Direct
156k156kOct 16, 2026Oct 16, 2026
155,804Oct 16, 2026

These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.

Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells red
1 active days
Oct 16 → Nov 16
LessMore

Beam Therapeutics Inc. Insider Activity FAQ

SEC Form 4 context

Who recently reported transactions at Beam Therapeutics Inc.?

Evans John M..

When was the latest reported open-market purchase?

No code-P purchase is available for this period.

When was the latest reported open-market sale?

Evans John M. reported a sale on Oct 16, 2026 valued at $600k. Read the SEC filing.

What is the recent purchase and sale balance?

Net open-market selling in the selected period was $599,595. Sales can occur for many non-investment reasons.

Where can I see the original SEC filing?

Every transaction row and latest-activity fact links to its original SEC filing.

What do these Form 4 transaction codes mean?

P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.